Alere is a world leader in rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology.
We are the scientists, specialists, lab technicians and more – all working to deliver reliable and actionable information through our rapid diagnostic tests.
Point-of-care diagnostics is a growing and dynamic industry helping to improve clinical and economic outcomes globally. Discover a variety of expert viewpoints on new innovations, insights, and impacts that are shaping the future of diagnostics around the world.
Alere products give providers, physicians and patients access to the right information at the right time.
Our products and services include tests to assist in the diagnosis and management of many cardiometabolic factors and conditions including cardiac markers, glucose and HbA1C, cholesterol levels, blood gases, and home monitoring for VAD and oral anticoagulation.
Our products and services include tests to assist in the diagnosis and management of many infectious diseases including HIV, Malaria, Syphilis, E. Coli, and Influenza.
Broad drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents. With 6 accredited laboratories and over 4,000 connected collection sites globally, we serve over 100,000 unique clients around the world.
Our innovative diagnostics provide reliable and actionable information that enables informed decision-making by healthcare professionals at the point-of-care.
Our rapid diagnostic products are changing how healthcare is delivered-extending diagnosis and health management from the lab, doctor's office and hospital into people's homes.
Alere™ Toxicology offers drug testing products and services that are used in a multitude of settings such as hospitals, clinics, physician offices, criminal justice, workplace, rehabilitation, occupational health clinics, and home testing.
Through our mission, we aim to improve clinical outcomes, reduce healthcare costs and deliver earnings growth to our investors.
Annual Meetings and Reports
Alere has a firmly established policy of conducting our affairs in compliance with the letter and spirit of the law and adhering to the principles of business ethics.
Connect with us.
Contact us for sales assistance, technical support or further information.
Step by step demos of our products in action.
The Clinical Laboratory Improvement Amendments (CLIA) program recently introduced the Individualized Quality Control Plan (IQCP) as a new quality control option for nonwaived testing. We are pleased to provide you with materials to support your IQCPs.
Alere Inc. is a major global developer, manufacturer and marketer of advanced medical diagnostic products.
Please select your country.
June 16, 2016 - Alere q HIV-1/2 Detect Point-of-Care Molecular HIV Assay Receives WHO Prequalification
July 14, 2014 - New Alere™ q Point-of-Care Early Infant Diagnosis Test Prototype Accurately Detects HIV in Infants with High Sensitivity and Specificity in Primary Health Clinics in Mozambique.
Discover how our innovative diagnostics deliver reliable and actionable information.
Here are the